Japan team transplants stem cells into brain to treat Parkinson's

Japanese researchers said Friday they have transplanted stem cells into the brain of a patient in the first stage of an innovative trial to cure Parkinson's disease.

The research team at Kyoto University injected induced Pluripotent Stem (iPS) cells -- which have the potential to develop into any cell in the body -- into the brain of a male patient in his fifties, the university said in a press release.

The man was stable after the operation, which was performed last month, and he will now be monitored for two years, the university added.

The researchers injected 2.4 million iPS cells into the left side of the patient's brain, in an operation that took about three hours.

If no problems are observed in the coming six months, they will implant another 2.4 million cells into the right side.

The iPS cells from healthy donors have been developed into the precursors of dopamine-producing brain cells, which are no longer present in people with Parkinson's disease.

The operation came after the university announced in July they would carry out the trial with seven participants aged between 50 and 69.

It is the first involving implanting stem cells into the brain to cure Parkinson's.

"I appreciate the patients for participating in the trial with courage and determination," Kyoto University professor Jun Takahashi told reporters on Friday, according to public broadcaster NHK.

Parkinson's disease is a chronic, degenerative neurological disorder that affects the body's motor system, often causing shaking and other difficulties in movement.

Worldwide, about 10 million people have the illness, according to the Parkinson's Disease Foundation.

Currently available therapies "improve symptoms without slowing or halting the disease progression," the foundation says.

The human trial comes after an earlier trial involving monkeys.

Researchers announced last year that primates with Parkinson's symptoms regained significant mobility after iPS cells were inserted into their brains.

They also confirmed that the iPS cells had not transformed into tumours during the two years after the implant.

iPS cells are created by stimulating mature, already specialised, cells back into a juvenile state -- basically cloning without the need for an embryo.

The cells can be transformed into a range of different types of cells, and their use is a key sector of medical research.